Inmune Bio (INMB) Interest Expenses (2017 - 2026)
Inmune Bio (INMB) posted Interest Expenses of $259000.0 for Q1 2026, down 52.48% sequentially from $545000.0 in Q4 2025, and down 97.24% YoY from $9.4 million in Q1 2025.
Inmune Bio (INMB) Interest Expenses (2017 - 2026) Analysis & Trends
Inmune Bio has reported Interest Expenses for 10 years, with the latest figure at $259000.0 in Q1 2026.
- Quarterly Interest Expenses fell 97.24% year-over-year to $259000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $259000.0 (down 97.24% YoY) and the FY2025 annual result came in at $34.7 million, up 35.12% from the prior year.
- Interest Expenses fell to $259000.0 in Q1 2026 per INMB's latest filing, from $545000.0 in the prior quarter.
- Over five years, Interest Expenses peaked at $525.0 million in Q3 2022 and troughed at $152000.0 in Q2 2025.
- A 5-year average of $42.7 million and a median of $884000.0 in 2023 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2024 and 2025: Interest Expenses jumped 3791.01% in 2024, then tumbled 99.17% in 2025.
- Over 5 years, Interest Expenses stood at $857000.0 in 2022, then increased by 3.15% to $884000.0 in 2023, then increased by 16.4% to $1.0 million in 2024, then tumbled by 47.04% to $545000.0 in 2025, then slumped by 52.48% to $259000.0 in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $259000.0, $545000.0, and $1.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 11.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 39.74 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 82.05 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -4.89 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 20.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 93.62 Mn |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 259,000.00 |
| Mar 31, 2026 | 259,000.00 |
| Dec 31, 2025 | 545,000.00 |
| Dec 31, 2025 | 545,000.00 |
| Sep 30, 2025 | 1.20 Mn |
| Sep 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 152,000.00 |
| Jun 30, 2025 | 152,000.00 |
| Mar 31, 2025 | 9.37 Mn |
| Mar 31, 2025 | 9.37 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Dec 31, 2024 | 1.03 Mn |
| Sep 30, 2024 | 145.00 Mn |
| Sep 30, 2024 | 145.00 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 23.81 Mn |
| Mar 31, 2024 | 23.81 Mn |